VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy

Negative allosteric modulators (NAMs) of metabotropic glutamate receptor subtype 5 (mGlu(5)) have potential applications in the treatment of fragile X syndrome, levodopa-induced dyskinesia in Parkinson disease, Alzheimer disease, addiction, and anxiety; however, clinical and preclinical studies rais...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Pharmacol Exp Ther
Главные авторы: Nickols, Hilary Highfield, Yuh, Joannes P., Gregory, Karen J., Morrison, Ryan D., Bates, Brittney S., Stauffer, Shaun R., Emmitte, Kyle A., Bubser, Michael, Peng, Weimin, Nedelcovych, Michael T., Thompson, Analisa, Lv, Xiaohui, Xiang, Zixiu, Daniels, J. Scott, Niswender, Colleen M., Lindsley, Craig W., Jones, Carrie K., Conn, P. Jeffrey
Формат: Artigo
Язык:Inglês
Опубликовано: The American Society for Pharmacology and Experimental Therapeutics 2016
Предметы:
Neuropharmacology
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4702078/
https://ncbi.nlm.nih.gov/pubmed/26503377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.115.226597
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы